Elan (ELN) Restructures Tysabri Collaboration w/ Biogen (BIIB); Will Get $3.25B Upfront
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
RBC Capital Downgrades Elan Corp (ELN) to Sector Perform
February 7, 2013 9:15 AM ESTRBC Capital downgraded Elan Corp (NYSE: ELN) from Outperform to Sector Perform with a price target of $11.00 (from $15.00) following sale of Tysabri rights.
For an analyst ratings summary and ratings history on Elan Corp... More
Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
February 6, 2013 3:50 PM ESTDeutsche Bank raised its price target on Buy-rated Biogen (NASDAQ: BIIB) from $160 to $170 following the news the company acquired 100% rights for Tysabri from ELAN (NYSE: ELN) for an upfront payment of $3.25B and contingent royalty payments based... More
Deutsche Bank Downgrades Elan Corp (ELN) to Hold; Post Tysabri Deal M&A Activity in Focus
February 6, 2013 3:46 PM ESTDeutsche Bank downgraded Elan Corp (NYSE: ELN) from Buy to Hold with a EUR 7.60 price target following the sale of Tysabri to Biogen.
The firm comments, "Elans decision to cede control of Tysabri to Biogen seems to be an attractive... More
